Skip to main content
SpringerLink
Log in

Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure

  • Chapter
Management of Heart Failure

  • 1582 Accesses

Abstract

Digoxin is recommended for patients with left ventricular systolic dysfunction who continue to have New York Heart Association functional class II–IV symptoms despite appropriate medical therapy and optimization of volume status. Diuretics are the mainstay of therapy for the removal of excess fluid in patients with heart failure (HF). They are equally important for use in patients with decompensated HF as well as in those with stable chronic HF to maintain euvolemia. This chapter will review the pharmacokinetics and appropriate use criteria of available cardiac glycosides and diuretics as well as drugs that are used primarily for their vasodilator properties in patients with HF. Newer agents such as Arginine Vasopressin Receptor Antagonists and Adenosine A1 Receptor Antagonists are also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.

    Article  PubMed  Google Scholar 

  2. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–89.

    Article  PubMed  Google Scholar 

  3. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1–194.

    Article  PubMed  Google Scholar 

  4. Akera T, Baskin SI, Tobin T, Brody TM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K +)- activated ATPase. Naunyn Schmiedebergs Arch Pharmacol. 1973;277:151–62.

    Article  CAS  PubMed  Google Scholar 

  5. Eisner DA, editor. The NA-K pump and its effectors in cardiac muscle. Ney York: Raven; 1991.

    Google Scholar 

  6. Wang W, Chen JS, Zucker IH. Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation. 1990;81:1959–66.

    Article  CAS  PubMed  Google Scholar 

  7. Thames MD. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents. Circ Res. 1979;44:8–15.

    Article  CAS  PubMed  Google Scholar 

  8. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation. 1989;80:65–77.

    Article  CAS  PubMed  Google Scholar 

  9. Torretti J, Hendler E, Weinstein E, Longnecker RE, Epstein FH. Functional significance of Na- K-ATPase in the kidney: effects of ouabain inhibition. Am J Physiol. 1972;222:1398–405.

    CAS  PubMed  Google Scholar 

  10. Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med. 1983;75:445–7.

    Article  CAS  PubMed  Google Scholar 

  11. Gheorghiade M, Adams Jr KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959–64.

    Article  PubMed  Google Scholar 

  12. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation. 1991;84:2181–6.

    Article  CAS  PubMed  Google Scholar 

  13. Kelly R. Pharmacological treatment of heart failure. New York: McGraw-Hill; 1996.

    Google Scholar 

  14. Ochs HR, Greenblatt DJ, Bodem G, Harmatz JS. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J. 1978;96:507–11.

    Article  CAS  PubMed  Google Scholar 

  15. Applefeld MM, Adir J, Crouthamel WG, Roffman DS. Digoxin pharmacokinetics in congestive heart failure. J Clin Pharmacol. 1981;21:114–20.

    Article  CAS  PubMed  Google Scholar 

  16. Gheorghiade M, St Clair J, St Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 1987;9:849–57.

    Article  CAS  PubMed  Google Scholar 

  17. Krum H, Bigger Jr JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol. 1995;25:289–94.

    Article  CAS  PubMed  Google Scholar 

  18. van Veldhuisen DJ, Man in ’t Veld AJ, Dunselman PH, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol. 1993;​22:1564–73.

    Article  PubMed  Google Scholar 

  19. Johnston GD, McDevitt DG. Is maintenance digoxin necessary in patients with sinus rhythm? Lancet. 1979;1:567–70.

    Article  CAS  PubMed  Google Scholar 

  20. Hull SM, Mackintosh A. Discontinuation of maintenance digoxin therapy in general practice. Lancet. 1977;2:1054–5.

    Article  CAS  PubMed  Google Scholar 

  21. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med. 1982;73:244–50.

    Article  CAS  PubMed  Google Scholar 

  22. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982;306:699–705.

    Article  CAS  PubMed  Google Scholar 

  23. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371–5.

    Article  CAS  PubMed  Google Scholar 

  24. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA. 1988;259:539–44.

    Google Scholar 

  25. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet. 1988;1:489–93.

    Google Scholar 

  26. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677–83.

    Article  CAS  PubMed  Google Scholar 

  27. Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 1991;17:743–51.

    Article  CAS  PubMed  Google Scholar 

  28. Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol. 1987;9 Suppl 2:S61–7.

    Article  PubMed  Google Scholar 

  29. Kromer EP, Elsner D, Riegger GA. Digoxin, converting-enzyme inhibition (quinapril), and the combination in patients with congestive heart failure functional class II and sinus rhythm. J Cardiovasc Pharmacol. 1990;16:9–14.

    Article  CAS  PubMed  Google Scholar 

  30. Davies RF, Beanlands DS, Nadeau C, et al. Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group. J Am Coll Cardiol. 1991;​18:1602–9.

    Article  CAS  PubMed  Google Scholar 

  31. Alicandri C, Fariello R, Boni E, Zaninelli A, Muiesan G. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study. J Cardiovasc Pharmacol. 1989;14 Suppl 8:S77–82.

    PubMed  Google Scholar 

  32. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1–7.

    Article  CAS  PubMed  Google Scholar 

  33. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993;22:955–62.

    Article  CAS  PubMed  Google Scholar 

  34. Adams Jr KF, Gheorghiade M, Uretsky BF, et al. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol. 1997;30:42–8.

    Article  PubMed  Google Scholar 

  35. Adams Jr KF, Gheorghiade M, Uretsky BF, et al. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J. 1998;​135:389–97.

    Article  CAS  PubMed  Google Scholar 

  36. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525–33.

    Google Scholar 

  37. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006;​113:2556–64.

    Article  PubMed  Google Scholar 

  39. Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA. 2009;302:2146–7.

    Article  PubMed  Google Scholar 

  40. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail. 2009;2:90–7.

    Article  CAS  PubMed  Google Scholar 

  41. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–11.

    Article  CAS  PubMed  Google Scholar 

  42. Adams Jr KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497–504.

    Article  CAS  PubMed  Google Scholar 

  43. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005;11:83–6.

    Article  CAS  PubMed  Google Scholar 

  44. Ather S, Peterson LE, Divakaran VG, et al. Digoxin treatment in heart failure – unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011;​150:264–9.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Adams Jr KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946–53.

    Article  CAS  PubMed  Google Scholar 

  46. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–8.

    Article  CAS  PubMed  Google Scholar 

  47. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol. 2008;​123:138–46.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999;99:1265–70.

    Article  CAS  PubMed  Google Scholar 

  49. Bosse GM, Pope TM. Recurrent digoxin overdose and treatment with digoxin-specific Fab antibody fragments. J Emerg Med. 1994;12:179–85.

    Article  CAS  PubMed  Google Scholar 

  50. Katz AI. Distribution and function of classes of ATPases along the nephron. Kidney Int. 1986;29:​21–31.

    Article  CAS  PubMed  Google Scholar 

  51. Valette H, Apoil E. Interaction between salicylate and two loop diuretics. Br J Clin Pharmacol. 1979;8:592–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Brater DC. Clinical pharmacology of loop diuretics in health and disease. Eur Heart J. 1992;13(Suppl G):10–4.

    Article  PubMed  Google Scholar 

  53. Knoben J. Clinical drug data. 6th ed. Hamilton: Drug Intelligence Publications; 1988.

    Google Scholar 

  54. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int. 1987;32:572–8.

    Article  CAS  PubMed  Google Scholar 

  55. Rudy DW, Gehr TW, Matzke GR, Kramer WG, Sica DA, Brater DC. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther. 1994;​56:39–47.

    Article  CAS  PubMed  Google Scholar 

  56. Schwartz S, Brater DC, Pound D, Green PK, Kramer WG, Rudy D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther. 1993;54:90–7.

    Article  CAS  PubMed  Google Scholar 

  57. Rose BD. Diuretics. Kidney Int. 1991;39:336–52.

    Article  CAS  PubMed  Google Scholar 

  58. Hropot M, Fowler N, Karlmark B, Giebisch G. Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int. 1985;28:477–89.

    Article  CAS  PubMed  Google Scholar 

  59. Velazquez H, Wright FS. Effects of diuretic drugs on Na, Cl, and K transport by rat renal distal tubule. Am J Physiol. 1986;250:F1013–23.

    CAS  PubMed  Google Scholar 

  60. Kunau Jr RT, Weller DR, Webb HL. Clarification of the site of action of chlorothiazide in the rat nephron. J Clin Invest. 1975;56:401–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Plotkin MD, Kaplan MR, Verlander JW, et al. Localization of the thiazide sensitive Na-Cl cotransporter, rTSC1 in the rat kidney. Kidney Int. 1996;​50:174–83.

    Article  CAS  PubMed  Google Scholar 

  62. Stanton BA, Kaissling B. Regulation of renal ion transport and cell growth by sodium. Am J Physiol. 1989;257:F1–10.

    CAS  PubMed  Google Scholar 

  63. Garg LC, Narang N. Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron. Kidney Int. 1987;31:918–22.

    Article  CAS  PubMed  Google Scholar 

  64. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;​349:1628–35.

    Article  CAS  PubMed  Google Scholar 

  65. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991;115:​360–6.

    Article  CAS  PubMed  Google Scholar 

  66. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983;309:1414–9.

    Article  CAS  PubMed  Google Scholar 

  67. Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther. 1992;17:155–64.

    Article  CAS  PubMed  Google Scholar 

  68. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:​1852–7.

    Article  CAS  PubMed  Google Scholar 

  69. Ramsay LE, Yeo WW, Jackson PR. Metabolic effects of diuretics. Cardiology. 1994;84 Suppl 2:48–56.

    Article  CAS  PubMed  Google Scholar 

  70. Bronner F. Renal calcium transport: mechanisms and regulation–an overview. Am J Physiol. 1989;​257:​F707–11.

    CAS  PubMed  Google Scholar 

  71. Friedman PA. Basal and hormone-activated calcium absorption in mouse renal thick ascending limbs. Am J Physiol. 1988;254:F62–70.

    CAS  PubMed  Google Scholar 

  72. Brater DC, editor. Contemporary issues in nephrology pharmacology of renal disease and hypertension. New York: Churchill Livingstone. 1987.

    Google Scholar 

  73. Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis. 1994;23:623–43.

    Article  CAS  PubMed  Google Scholar 

  74. Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther. 1979;210:​386–90.

    CAS  PubMed  Google Scholar 

  75. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int. 1984;26:183–9.

    Article  CAS  PubMed  Google Scholar 

  76. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90–6.

    Article  CAS  PubMed  Google Scholar 

  77. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med. 1979;91:744–5.

    Article  CAS  PubMed  Google Scholar 

  78. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;​28:376–82.

    Article  CAS  PubMed  Google Scholar 

  79. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol. 1981;15:90–6.

    CAS  PubMed  Google Scholar 

  80. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;(3):CD003178.

    Google Scholar 

  81. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16:277–84.

    Article  PubMed  Google Scholar 

  82. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  83. Abildgaard U, Aldershvile J, Ring-Larsen H, et al. Bed rest and increased diuretic treatment in chronic congestive heart failure. Eur Heart J. 1985;6:​1040–6.

    CAS  PubMed  Google Scholar 

  84. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:​198–203.

    Article  CAS  PubMed  Google Scholar 

  85. Fliser D, Zurbruggen I, Mutschler E, et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int. 1999;55:629–34.

    Article  CAS  PubMed  Google Scholar 

  86. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed). 1986;292:1351–3.

    Article  CAS  Google Scholar 

  87. Wald H, Scherzer P, Popovtzer MM. Na, K-ATPase in isolated nephron segments in rats with experimental heart failure. Circ Res. 1991;68:1051–8.

    Article  CAS  PubMed  Google Scholar 

  88. Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med. 1983;​99:405–6.

    Article  CAS  PubMed  Google Scholar 

  89. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:​2028–35.

    Article  CAS  PubMed  Google Scholar 

  90. Tsutamoto T, Sakai H, Wada A, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2252–3.

    Article  CAS  PubMed  Google Scholar 

  91. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV–efficacy and quality of life. Eur J Heart Fail. 2003;5:793–801.

    Article  CAS  PubMed  Google Scholar 

  92. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–8.

    Article  PubMed  Google Scholar 

  93. Chiong JR, Cheung RJ. Loop diuretic therapy in heart failure: the need for solid evidence on a fluid issue. Clin Cardiol. 2010;33:345–52.

    Article  PubMed  Google Scholar 

  94. Martins J, Lourenco P, Araujo JP, et al. Prognostic implications of diuretic dose in chronic heart failure. J Cardiovasc Pharmacol Ther. 2011;16:185–91.

    Article  CAS  PubMed  Google Scholar 

  95. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010;160:264–71 e1.

    Article  CAS  PubMed  Google Scholar 

  96. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–41.

    Article  PubMed  Google Scholar 

  97. Butler J, Chirovsky D, Phatak H, McNeill A, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010;3:726–45.

    Article  PubMed  Google Scholar 

  98. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;​27:1431–9.

    Article  PubMed Central  PubMed  Google Scholar 

  99. Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res. 1998;38:​198–205.

    Article  CAS  PubMed  Google Scholar 

  100. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995;92:1013–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  101. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–6.

    Article  CAS  PubMed  Google Scholar 

  102. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:​1963–71.

    Article  CAS  PubMed  Google Scholar 

  103. Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.

    Article  CAS  PubMed  Google Scholar 

  104. Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–31.

    Article  CAS  PubMed  Google Scholar 

  105. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation. 2008;118:410–21.

    Article  PubMed  Google Scholar 

  106. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641–7.

    Article  CAS  PubMed  Google Scholar 

  107. Pelleg A, Porter RS. The pharmacology of adenosine. Pharmacotherapy. 1990;10:157–74.

    CAS  PubMed  Google Scholar 

  108. Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs. 2001;61:1387–93.

    Article  CAS  PubMed  Google Scholar 

  109. Munger KA, Jackson EK. Effects of selective A1 receptor blockade on glomerular hemodynamics: involvement of renin-angiotensin system. Am J Physiol. 1994;267:F783–90.

    CAS  PubMed  Google Scholar 

  110. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008;14:631–40.

    Article  CAS  PubMed  Google Scholar 

  111. Ponikowski P, Mitrovic V, O’Connor CM, et al. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Eur J Heart Fail. 2010;12:1238–46.

    Article  CAS  PubMed  Google Scholar 

  112. Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:​1419–28.

    Article  PubMed  Google Scholar 

  113. Weatherley BD, Cotter G, Dittrich HC, et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail. 2010;​16:25–35.

    Article  CAS  PubMed  Google Scholar 

  114. Li Z, Tenhoor C, Marbury T, et al. Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects. J Clin Pharmacol. 2011;51:1004–14.

    Article  CAS  PubMed  Google Scholar 

  115. Gottlieb SS, Ticho B, Deykin A, et al. Effects of BG9928, an adenosine A1 receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol. 2011;51:899–907.

    Article  CAS  PubMed  Google Scholar 

  116. Cohn JN. Blood pressure and cardiac performance. Am J Med. 1973;55:351–61.

    Article  CAS  PubMed  Google Scholar 

  117. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation. 1973;48:5–8.

    Article  CAS  PubMed  Google Scholar 

  118. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977;297:27–31.

    Article  CAS  PubMed  Google Scholar 

  119. Imperial ES, Levy MN, Zieske H. OUTFlow resistance as an independent determinant of cardiac performance. Circ Res. 1961;9:1148.

    Article  Google Scholar 

  120. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol. 1963;204:604.

    CAS  PubMed  Google Scholar 

  121. Franciosa JA, Limas CJ, Guiha NH, Rodriguera E, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972;1:650–4.

    Article  CAS  PubMed  Google Scholar 

  122. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas CJ. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med. 1974;291:​587–92.

    Article  CAS  PubMed  Google Scholar 

  123. Franciosa JA, Cohn JN. Effects of minoxidil on hemodynamics in patients with congestive heart failure. Circulation. 1981;63:652–7.

    Article  CAS  PubMed  Google Scholar 

  124. Franciosa JA, Mikulic E, Cohn JN, Jose E, Fabie A. Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure. Circulation. 1974;50:1020–4.

    Article  CAS  PubMed  Google Scholar 

  125. Franciosa JA, Pierpont G, Cohn JN. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med. 1977;86:388–93.

    Article  CAS  PubMed  Google Scholar 

  126. Miller RR, Awan NA, Maxwell KS, Mason DT. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med. 1977;297:303–7.

    Article  CAS  PubMed  Google Scholar 

  127. Schreiber R, Maier PT, Gunnar RM, Loeb HS. Hemodynamic improvement following a single dose of oral phentolamine. Administration in patients with chronic low output cardiac failure. Chest. 1979;76:571–5.

    Article  CAS  PubMed  Google Scholar 

  128. McNamara D. Neurohormonal and cytokine activation in heart failure. In: Dekker M, editor. Heart failure: a comprehensive guide diagnosis and treatment. 1st ed. Informa Healthcare, London. 2005. pp. 117–36.

    Google Scholar 

  129. Leimbach Jr WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic oUTFlow in patients with heart failure. Circulation. 1986;73:913–9.

    Article  PubMed  Google Scholar 

  130. Katz AM. The myocardium in congestive heart failure. Am J Cardiol. 1989;63:12A–6.

    Article  CAS  PubMed  Google Scholar 

  131. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:​297–309.

    Article  CAS  PubMed  Google Scholar 

  132. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–52.

    Article  CAS  PubMed  Google Scholar 

  133. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429–35.

    Google Scholar 

  134. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.

    Article  CAS  PubMed  Google Scholar 

  135. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–16.

    Article  CAS  PubMed  Google Scholar 

  136. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178–87.

    Article  CAS  PubMed  Google Scholar 

  137. Cardillo C, Kilcoyne CM, Cannon 3rd RO, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:90–5.

    Article  CAS  PubMed  Google Scholar 

  138. Franciosa JA, Taylor AL, Cohn JN, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:​128–35.

    Article  PubMed  Google Scholar 

  139. Kahn DF, Duffy SJ, Tomasian D, et al. Effects of black race on forearm resistance vessel function. Hypertension. 2002;40:195–201.

    Article  CAS  PubMed  Google Scholar 

  140. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511–7.

    Article  PubMed  Google Scholar 

  141. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436–43.

    Article  CAS  PubMed  Google Scholar 

  142. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.

    Article  CAS  PubMed  Google Scholar 

  143. Vita JA. Nitric oxide and vascular reactivity in African American patients with hypertension. J Card Fail. 2003;9:S199–204; discussion S5–9.

    Article  CAS  PubMed  Google Scholar 

  144. Schofer J, Hobuss M, Aschenberg W, Tews A. Acute and long-term haemodynamic and neurohumoral response to nisoldipine vs captopril in patients with heart failure: a randomized double-blind study. Eur Heart J. 1990;11:712–21.

    CAS  PubMed  Google Scholar 

  145. van den Toren EW, van Veldhuisen DJ, van Bruggen A, van den Broek SA, van Gilst WH, Lie KI. Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. Int J Cardiol. 1996;53:37–43.

    Article  PubMed  Google Scholar 

  146. Dei Cas L, Metra M, Ferrari R, Visioli O. Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. Cardiovasc Drugs Ther. 1993;7:103–10.

    Article  CAS  PubMed  Google Scholar 

  147. Magorien RD, Leier CV, Kolibash AJ, Barbush TJ, Unverferth DV. Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure. Circulation. 1984;​70:884–90.

    Article  CAS  PubMed  Google Scholar 

  148. Walsh RW, Porter CB, Starling MR, O’Rourke RA. Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure. J Am Coll Cardiol. 1984;3:1044–50.

    Article  CAS  PubMed  Google Scholar 

  149. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Am J Cardiol. 1990;66:33I–40I.

    Google Scholar 

  150. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319:385–92.

    Google Scholar 

  151. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;​83:52–60.

    Article  CAS  PubMed  Google Scholar 

  152. Packer M, Lee WH, Medina N, Yushak M, Bernstein JL, Kessler PD. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 1987;10:1303–11.

    Article  CAS  PubMed  Google Scholar 

  153. Guazzi MD, Cipolla C, Della Bella P, Fabbiocchi F, Montorsi P, Sganzerla P. Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle. Am Heart J. 1984;108:116–23.

    Article  CAS  PubMed  Google Scholar 

  154. Shimoni A, Maor-Kendler Y, Neuman Y. Verapamil-induced acute right heart failure. Am Heart J. 1996;​132:193–4.

    Article  CAS  PubMed  Google Scholar 

  155. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954–61.

    Article  CAS  PubMed  Google Scholar 

  156. Packer M. Calcium channel blockers in chronic heart failure. The risks of “physiologically rational” therapy. Circulation. 1990;82:2254–7.

    Article  CAS  PubMed  Google Scholar 

  157. Gradman AH. Hemodynamic effects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function. Am Heart J. 1992;123:273–8.

    Article  CAS  PubMed  Google Scholar 

  158. Capewell S, Wathen CG, Muir AL. Central and peripheral haemodynamic responses to felodipine in congestive heart failure. Eur J Clin Pharmacol. 1991;41:95–8.

    Article  CAS  PubMed  Google Scholar 

  159. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107–14.

    Article  CAS  PubMed  Google Scholar 

  160. Packer M. The Second “Prospective, Randomized Amlodipine Survival Assessment (PRAISE-2)” Study In: Results from late-breaking clinical trials sessions, ACC. 2000;2000.

    Google Scholar 

  161. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856–63.

    Article  CAS  PubMed  Google Scholar 

  162. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:​1531–40.

    Google Scholar 

  163. Bayley S, Valentine H, Bennett ED. The haemodynamic responses to incremental doses of intravenous nitroglycerin in left ventricular failure. Intensive Care Med. 1984;10:139–45.

    Article  CAS  PubMed  Google Scholar 

  164. Natarajan D, Khurana TR, Karhade V, Nigam PD. Sustained hemodynamic effects with therapeutic doses of intravenous nitroglycerin in congestive heart failure. Am J Cardiol. 1988;62:319–21.

    Article  CAS  PubMed  Google Scholar 

  165. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol. 1996;77:41C–51.

    Article  CAS  PubMed  Google Scholar 

  166. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923–31.

    Article  CAS  PubMed  Google Scholar 

  167. Webster MW, Sharpe DN, Coxon R, et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol. 1989;63:217–21.

    Article  CAS  PubMed  Google Scholar 

  168. Dakak N, Makhoul N, Merdler A, et al. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. Eur Heart J. 1993;14:836–44.

    Article  CAS  PubMed  Google Scholar 

  169. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577–84.

    Article  CAS  PubMed  Google Scholar 

  170. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P. Vasodilators in the management of acute heart failure. Crit Care Med. 2008;36:S95–105.

    Article  CAS  PubMed  Google Scholar 

  171. Elkayam U, Weber L, Torkan B, McKay CR, Rahimtoola SH. Comparison of hemodynamic responses to nifedipine and nitroprusside in severe chronic congestive heart failure. Am J Cardiol. 1984;53:1321–5.

    Article  CAS  PubMed  Google Scholar 

  172. Tesfamariam B, Halpern W. Endothelium-dependent and endothelium-independent vasodilation in resistance arteries from hypertensive rats. Hypertension. 1988;11:440–4.

    Article  CAS  PubMed  Google Scholar 

  173. Hamilton MA, Stevenson LW, Child JS, Moriguchi JD, Woo M. Acute reduction of atrial overload during vasodilator and diuretic therapy in advanced congestive heart failure. Am J Cardiol. 1990;65:​1209–12.

    Article  CAS  PubMed  Google Scholar 

  174. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002;39:1623–9.

    Article  CAS  PubMed  Google Scholar 

  175. Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol. 1989;63:461–4.

    Article  CAS  PubMed  Google Scholar 

  176. Mann T, Cohn PF, Holman LB, Green LH, Markis JE, Phillips DA. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732–8.

    Article  CAS  PubMed  Google Scholar 

  177. Vesey CJ, Cole PV. Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br J Anaesth. 1985;57:​148–55.

    Article  CAS  PubMed  Google Scholar 

  178. Elkayam U, Akhter MW, Tummala P, Khan S, Singh H. Nesiritide: a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther. 2002;7:181–94.

    Article  CAS  PubMed  Google Scholar 

  179. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–53.

    Article  CAS  PubMed  Google Scholar 

  180. Mentzer Jr RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007;49:716–26.

    Article  CAS  PubMed  Google Scholar 

  181. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–91.

    Article  CAS  PubMed  Google Scholar 

  182. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–5.

    Article  CAS  PubMed  Google Scholar 

  183. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA. 2006;296:​1465–6.

    Article  CAS  PubMed  Google Scholar 

  184. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084–90.

    Article  CAS  PubMed  Google Scholar 

  185. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.

    Article  PubMed  Google Scholar 

  186. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.

    Google Scholar 

  187. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol. 2007;612:65–87.

    Article  PubMed  Google Scholar 

  188. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182–90.

    Article  CAS  PubMed  Google Scholar 

  189. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429–39.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Emory UniversitySchool of Medicine, 1462 Clifton Road NE, Suite 503, Atlanta, GA, 30322, USA

    Catherine Norton Marti MD, MSc & Javed Butler MD, MPH

  2. Department of Cardiology, Emory University School of Medicine, Center for Heart Failure Therapy, 1365 Clifton Road NE, Suite AT 430, Atlanta, GA, 30322, USA

    Robert T. Cole MD

  3. Department of Cardiology, Larissa University Hospital, 1425, 411 10, Larissa, Greece

    Gregory Giamouzis MD

Authors
  1. Catherine Norton Marti MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert T. Cole MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory Giamouzis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javed Butler MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Norton Marti MD, MSc .

Editor information

Editors and Affiliations

  1. Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA

    Ragavendra R. Baliga

  2. Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Colombus, Ohio, USA

    Garrie J. Haas

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Marti, C.N., Cole, R.T., Giamouzis, G., Butler, J. (2015). Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure. In: Baliga, R., Haas, G. (eds) Management of Heart Failure. Springer, London. https://doi.org/10.1007/978-1-4471-6657-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6657-3_4

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6656-6

  • Online ISBN: 978-1-4471-6657-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation